A Pilot Study Using Gut-Directed Hypnotherapy for Hospitalized Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Stanford, California, United States, 94305
- Stanford University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults admitted to the GI inpatient service with expected length of stay >24 hours
- Prior diagnosis of a disorder of gut-brain interaction, esophageal disorder, or inflammatory bowel disease
- Reason for hospitalization related to symptom management for exacerbation of visceral pain and/or nausea.
Exclusion Criteria:
- Currently using hypnosis
- severe developmental delay or cognitive impairment
- serious mental illness (i.e. psychosis or dissociation)
- hearing impairment
- Non-English speaking
- enrolled in another trial for GI symptom management
- admitted for GI procedure
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Hypnosis
Participants will undergo gut-directed hypnotherapy via a phone intervention (10 minute recording, at least once daily while hospitalized) and for as much as participant would like for the 3 month duration of the study.
|
Participants will undergo a self-directed gut-directed hypnosis intervention over the telephone.
|
|
Sham Comparator: Education
Participants will listen to educational recording (10 minute recording, at least once daily while hospitalized) and for as much as participant would like for the 3 month duration of the study.
|
Participants will listen to educational material over the telephone about their gastrointestinal symptoms.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recruitment rate
Time Frame: Up to 1 year.
|
Recruitment rate is the proportion enrolled among eligible patients approached.
|
Up to 1 year.
|
|
Number of participants who adhered to intervention
Time Frame: 3 months.
|
Proportion of participants completing ≥1 hypnosis session during hospitalization and total number of listens
|
3 months.
|
|
Retention rate
Time Frame: 3 months.
|
Retention rate is defined as survey completion at baseline, 1 week, 1 month, and 3 months.
|
3 months.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Irene Sonu, MD, Stanford University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Signs and Symptoms, Digestive
- Intestinal Diseases
- Digestive System Diseases
- Gastrointestinal Diseases
- Colonic Diseases
- Gastroenteritis
- Colonic Diseases, Functional
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Irritable Bowel Syndrome
- Abdominal Pain
- Inflammatory Bowel Diseases
- Esophageal Diseases
Other Study ID Numbers
Other Study ID Numbers
- 83851
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.